Send to

Choose Destination
Evid Based Complement Alternat Med. 2017;2017:7083016. doi: 10.1155/2017/7083016. Epub 2017 Jun 15.

Cardioprotection against Heart Failure by Shenfu Injection via TGF-β/Smads Signaling Pathway.

Ni J1,2,3,4, Shi Y2,3,4, Li L2,3,4, Chen J2,3,4, Li L2,3,4, Li M2,3,4, Zhu J2,3,4, Zhu Y2,3,4, Fan G1,2,3,4.

Author information

First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 300193, China.
Tianjin State Key Laboratory of Modern Chinese Medicine, Tianjin 300193, China.
Ministry of Education, Key Laboratory of Formula of Traditional Chinese Medicine, Tianjin 300193, China.
Tianjin Key Laboratory of Traditional Chinese Medicine Pharmacology, Tianjin University of Traditional Chinese Medicine, Tianjin 300193, China.



To explore the potential cardioprotective mechanism of Shenfu injection (SFI) against heart failure (HF) by attenuating myocardial fibrosis and cardiac remodeling.


Four weeks after myocardial infarction (MI), adult male Sprague Dawley rats were randomized for 4-week treatment with Valsartan, SFI, or vehicle. Echocardiography and hemodynamics were applied to evaluate cardiac functions. Myocardia of coronary artery ligated (CAD) rats were observed to investigate changes in cardiac structure and function. Our findings suggest that treatment with SFI could inhibit progression of myocardial fibrosis and attenuate cardiac remodeling. In addition, SFI decreased expression of Smad2 and Smad3, while increasing the expression of Smad7 through regulation of TGF-β/Smads signaling pathway.


Treatment with SFI in Sprague Dawley rats improves ventricular structure and function and reduces cardiac fibrosis by ameliorating TGF-β/Smads signaling pathway after ventricular remodeling.

Supplemental Content

Full text links

Icon for Hindawi Limited Icon for PubMed Central
Loading ...
Support Center